Skip to main content

Table 3 Clinical endpoints in immunocompromised (Study) patients according to ventilation subgroup

From: Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

Clinical endpoints

IMV

(n = 462)

NIV

(n = 63)

NIV failure

(n = 59)

p Value

Duration of mechanical ventilation, d, median (Q1–Q3)

8.0 (4.0–14.0)

8.0 (5.0–15.0)

0.4352

Progression/regression of ARDSa, n (%)

 No change

161 (40.1)

18 (32.1)

22 (43.1)

0.4449

 Progression

43 (10.7)

5 (8.9)

7 (13.7)

0.7199

 Regression

103 (25.7)

4 (7.1)b

16 (31.4)c

0.0045

 Resolution

94 (23.44)

29 (51.8)b

6 (11.8)c

< 0.0001

Limitation of life-sustaining measures, n (%)

 Decision to withhold life-sustaining measures

124 (26.8)

18 (28.6)

16 (27.1)

0.9587

 Decision to withdraw life-sustaining measures

101 (21.9)

14 (22.2)

14 (23.7)

0.9480

 Decision to withhold or withdraw life-sustaining measures

154 (33.3)

21 (33.3)

20 (33.9)

0.9962

  Before IMV or NIV start

1 (0.6)

0 (0.0)

1 (5.0)

0.2062

ICU mortalityd, n (%)

214 (46.3)

18 (28.6)b

34 (57.6)c

0.0043

Hospital mortalitye, n (%)

 All patients

242 (52.8)

25 (39.7)

37 (62.7)c

0.0362

 Patients with limitations of life-sustaining measuresf

137 (89.0)

17 (81.0)

19 (95.0)

0.3803

  1. Abbreviations: ARDS Acute respiratory distress syndrome, IMV Patients invasively ventilated from day 1, independently of the type of support received after the eventual extubation, NIV Patients treated exclusively with noninvasive ventilation, from day 1 to study exit, independently of outcome, NIV failure Patients initially treated with noninvasive ventilation and subsequently intubated during the study period, Q 1 First quartile, Q 3 Third quartile
  2. aChange in ARDS severity (according Berlin definition) was not evaluable for 76 immunocompromised patients (61 IMV, 7 NIV, and 8 NIV failure)
  3. bStatistically significant different from the IMV group
  4. cStatistically significant different from the NIV group
  5. dMortality is defined as mortality at ICU discharge or at the 90th day in ICU after onset of acute hypoxemic respiratory failure, whichever event occurred first
  6. eMortality is defined as mortality at hospital discharge or at the 90th day in hospital, after onset of acute hypoxemic respiratory failure, whichever event occurred first
  7. fMortality assessed in patients with a decision to withhold or withdraw life-sustaining measures
  8. Note: Bold p values represent a statistically significant difference among the three groups